NetworkNewsBreaks Archive - Page 2134 of 2221

ThursdayMay 04, 2017 1:25 pm

NetworkNewsBreaks – Aegis Capital Maintains ‘Buy’ Rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital has reiterated a ‘Buy’ rating and issued a price target of $25 on shares of Concert Pharmaceuticals, Inc.’s (NASDAQ: CNCE) stock. The news follows the company’s recently reported financial results for the first quarter of 2017, including revenue of $20,000 for the quarter. The analyst noted that because Concert is a clinical stage development company, the firm focuses less on the quarterly financials and more on events surrounding clinical trials and deal announcements. During the first quarter, Concert entered an asset purchase agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for CTP-656. Per the agreement, Vertex will pay Concert up…

ThursdayMay 04, 2017 1:23 pm

NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Reiterated with ‘Buy’ at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $63 on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) following the company’s recent financial results for the first quarter ended March 31, 2017. The company reported that cash, cash equivalents, and investments at the end of the quarter totaled $207.9 million. The analyst noted that because Aerie is a clinical stage development company, the firm is more focused on upcoming catalysts than quarterly financials. Catalysts for the company include the completion of the Rocket 4 trial; the upcoming Mercury 2 three-month efficacy and safety readout for Roclatan that is expected in…

ThursdayMay 04, 2017 1:20 pm

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating on Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Following Vanda Pharmaceuticals, Inc.’s (NASDAQ: VNDA) first quarter 2017 results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $24 on shares of the company’s stock. The company reported net product sales of $37.4 million in the first quarter of 2017 and reaffirmed its net product sales guidance for 2017 of $165 million to $175 million. The Aegis analyst noted that the company has expanded its sales team for Fanapt®, which should drive growth in the third and fourth quarter of this year. Data from three trials that the analyst cited as catalysts for the year is also…

ThursdayMay 04, 2017 1:19 pm

NetworkNewsBreaks – Aegis Capital Issues ‘Buy’ Rating on Soligenix, Inc. (NASDAQ: SNGX)

Aegis Capital has issued a ‘Buy’ rating and price target of $7 on shares of Soligenix, Inc.’s (NASDAQ: SNGX) stock. The analyst cites the recent approval by the FDA to advance a pivotal phase 3 clinical trial evaluating SGX942 for the treatment of oral mucositis in head and neck cancer (HNC) patients being treated with chemoradiation (CRT). Soligenix plans to initiate this study in the second quarter of 2017. The analyst also noted the company has recently reached important milestones in its development of a vaccine against ricin poisoning, with several data presentations from animal models. For more information, visit…

ThursdayMay 04, 2017 8:58 am

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Offers Intriguing Opportunity to Capitalize on Explosive Chinese Consumer Market Growth Projections

Understanding that an economy solely based on exports will ultimately implode, China has begun turning inward to expand its national economic drivers. With a population of almost 1.4 billion, China represents a huge new consumer market, and Moxian, Inc. (NASDAQ: MOXC) is poised to capitalize on the significant economic shift occurring in China and other parts of Asia by serving businesses that feed the demands of the new Chinese consumer. “With offices strategically located in China, Malaysia, and Hong Kong, Moxian provides small- and medium-sized businesses cutting edge turnkey solutions to attract and maintain customers. The company’s strategy is to…

ThursdayMay 04, 2017 8:56 am

NetworkNewsBreaks – GreeneStone Healthcare Corp. (GRST) Combating Devastating Effects of Substance Abuse on Florida’s Youth and Young Adults

Addiction is a chronic global problem with devastating effects for both youth and adults. For Floridians, the combination of rampant drug trafficking, widespread alcohol consumption, and the reputation for being a spring break party destination has made addiction a critical, statewide crisis—particularly for Florida’s youth. GreeneStone Healthcare Corp. (OTCQB: GRST) is working to help alleviate the problem of addiction by offering lifesaving addiction and rehabilitation treatment services to Floridians through its recently acquired Seastone Drug Rehab facility, located in Delray Beach, Florida. “The company, which offers addiction and rehabilitation treatment services, some of which include counseling, coaching, intervention, psychological assessment,…

WednesdayMay 03, 2017 1:54 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PIRS 43.04% – News: Enters strategic collaboration in respiratory diseases with AstraZeneca NYMX 22.16% – News: Files for Fexapotide Triflutate marketing authorization in Europe TECR 16.95% – News: Announces new product, Novokid + for head lice MTBC 14.00% – News: Discusses TalkEHR initiative in webcast WKHS 7.91% – News: Unveils electric pickup truck designed for the fleet market ESSI 7.87% – News: Signs content development and licensing agreement with Roaring Lion Tours AMMA 5.88%…

WednesdayMay 03, 2017 1:52 pm

NetworkNewsBreaks – SeeThruEquity Issues Coverage Update on Medical Transcription Billing, Corp. (NASDAQ: MTBC)

SeeThruEquity this week issued an update on Medical Transcription Billing, Corp. (NASDAQ: MTBC). The company recently pre-announced first quarter 2017 results with revenues of $8.2 million, a 60% increase over the same period in 2016. The growth has been primarily attributed to the recent acquisition of MediGain LLC, a Texas-based medical billing specialist, and its subsidiary, Millennium Practice Management Associates, LLC. The analyst noted that Aegis will update coverage following MTBC’s plans for an upcoming reverse stock split. For more information, visit www.mtbc.com About MTBC MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary…

WednesdayMay 03, 2017 1:51 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, $28 PT on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $28 on Revance Therapeutics, Inc. (NASDAQ: RVNC) after the company issued a protocol update on its phase 2 plantar fasciitis (PF) trial. Revance said it has expanded the phase 2 trial to a multi-center protocol with three centers, and changes were also made to the trial’s primary and secondary endpoints. The American Orthopaedic Foot and Ankle Score (AOFAS) will now be the secondary endpoint to provide foot functionality data. The new primary endpoint will be visual analog scale (VAS), which should provide foot pain data. Revance said it expects…

WednesdayMay 03, 2017 1:48 pm

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating, $31 PT on Neurotrope, Inc. (NASDAQ: NTRP)

Aegis Capital this week issued a ‘Buy’ rating and price target of $31 on shares of Neurotrope, Inc.’s (NASDAQ: NTRP) stock. The company recently released positive top-line results from its phase 2 study of Bryostatin-1 in patients with moderate to severe Alzheimer's disease (AD). Results from the study demonstrate that AD patients receiving Bryostatin-1 had an improvement in their cognitive abilities compared with a decline in the placebo patients. Aegis analyst Robert LeBoyer said he believes that the study met its objective of showing that Bryostatin-1 has adequate activity and data to move forward into a bigger study with a longer…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks